Drug Trial Radar · NCT03650270
Childhood Convulsive Status Epilepticus Management In A Resource Limited Setting
Last checked: Nov 19, 2026Latest source record: Aug 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
198
Actual
Start
Mar 1, 2015
Primary completion
Mar 1, 2018
Study completion Mar 1, 2018
Sponsor
- Lead sponsor
- University of Cape TownAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 28, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 month, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Convulsive status epilepticus (CSE) is a potentially devastating condition which can result in significant morbidity and mortality. Studies addressing status epilepticus in children are rare and there is a paucity of large randomised controlled trials in children looking at forms of drug treatment for SE. There is consistency worldwide in guidelines for first line treatment of CSE with benzodiazepines, with slight variations in type and route of administration of agents. Second line therapy usually entails phenobarbital or phenytoin parenterally. Both repeated phenobarbital loading doses and midazolam infusions have been shown to be effective and safe in the management of established convulsive SE, but there are no prospective randomized controlled trials comparing the two in children. Our study has been undertaken to review 2 existing, and routinely used, interventions for children presenting to our center with acute convulsive seizures. In order to permit comparable data to be collected we are randomly allocating these standard interventions prospectively. This is in order to compare the efficacy and safety of two treatment protocols (phenobarbital vs phenytoin and midazolam) both of which as stated are already part of existing standard protocols internationally and in South Africa. Parenteral phenobarbital is a safe, affordable and easy to use drug in the management of status epilepticus especially for poorly resourced communities where undertaking infusions may be unsafe, time consuming or unavailable. We hypothesize that repeated phenobarbital loading is as effective and safe, or more so, than phenytoin followed by midazolam infusion in the management of established and refractory childhood convulsive SE. If proven, then the former would be a viable option for all health care workers with access to intravenous routes (including Day hospitals) where infusions are unsafe, time consuming or unavailable.
Conditions
- Pediatric Status Epilepticus
Interventions
PhenobarbitalDrug
Three repeated doses of pareneteral phenobarbital was compared to a single parenteral infusion of phenytoin followed by an infusion of parenteral midazolam
Primary outcomes
What the sponsor says the trial is designed to measure.
- Differences in anticonvulsant efficacy between different second-line anticonvulsant treatment protocolsTime frame: Up to 24 hours from the time the patient was admitted.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Red Cross War Memorial Children's Hospital
Cape Town, Western Cape, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.